Table 3. Bivariate associations for characteristics associated with recent receptive syringe and cooker use.
| Recent Receptive Syringe Sharing(n = 345) | Recent Receptive Cooker Use(n = 345) | |||
| RR | 95% CI | RR | 95% CI | |
| Person-level characteristics of the “at-risk” HCV-negative injection partner | ||||
| Female vs. male gender | 1.30 | 0.50–3.40 | 1.50 | 0.66–3.41 |
| Age at enrollment | ||||
| 16 to 24 years | ref | ref | ||
| 25 to 30 years | 0.94 | 0.40–2.21 | 0.80 | 0.30–1.76 |
| 31 to 44 years | 2.70 | 0.49–15.12 | 2.20 | 0.41–11.68 |
| Non-white vs. white | 1.80 | 0.70–4.80 | 1.90 | 0.83–4.24 |
| Completed High School | 1.00 | 0.40–2.72 | 1.00 | 0.44–2.48 |
| Homeless/marginally housed† | 1.18 | 0.60–2.39 | 1.62 | 0.81–3.26 |
| Ever been in jail/prison | 1.45 | 0.44–4.76 | 1.50 | 0.50–4.90 |
| Ever in drug treatment | 0.59 | 0.23–1.54 | 0.69 | 0.30–1.60 |
| Age initiated injection drug use | ||||
| 10 to 14 years old | ref | ref | ||
| 15 to 18 years old | 0.32 | 0.08–1.30 | 0.29 | 009–0.95 |
| 19 to 38 years old | 0.50 | 0.11–2.00 | 0.66 | 0.21–2.06 |
| Partnership characteristics | ||||
| Gender/HCV composition | ||||
| HCV-serodiscordant male-male | ref | ref | ||
| Male HCV+, female HCV− | 1.51 | 0.41–5.58 | 0.90 | 0.30–2.08 |
| Female HCV+, male HCV− | 3.02 | 0.55–14.03 | 1.80 | 0.49–6.12 |
| Age/HCV composition | ||||
| HCV- injection partner ≥3 years younger | 0.81 | 0.10–5.40 | 4.10 | 0.65–28.55 |
| HCV- injection partner +/−3 years of injection partner | ref | ref | ||
| HCV- injection partner ≥3 years older | 0.93 | 0.19–4.80 | 3.52 | 0.81–15.63 |
| Sex with injection partner† | 2.94 | 1.43–6.04** | 2.50 | 1.31–4.80** |
| Cohabitated with injection partner† | ||||
| No cohabitation in prior month | ref | ref | ||
| Cohabited 1–28 days in prior month | 2.85 | 1.38–5.91** | 4.61 | 2.10–10.36*** |
| Cohabited ≥28 days in prior month | 5.30 | 1.90–14.72** | 5.35 | 1.85–15.40** |
| Known injection partner <1 year | ||||
| Duration injecting with partner | ||||
| < = 1 month | 0.94 | 0.35–2.5 | 2.66 | 0.81–8.71 |
| 1–6 month | 1.21 | 0.38–3.83 | 2.73 | 0.74–10.05 |
| 7–12 month | 0.40 | 0.07–2.13 | 0.97 | 0.19–5.06 |
| >12 months | ref | ref | ||
| Injecting Network | ||||
| Partner is only person participant reports injecting with† | ref | ref | ||
| Participant injected with 1–3 other people† | 0.98 | 0.52–1.88 | 1.21 | 0.54–2.72 |
| Participant injected with 4 or more other people† | 0.59 | 0.25–1.43 | 0.95 | 0.35–2.56 |
| Number of study visits partnership completed(per study visit) | 0.93 | 0.86–1.00* | 0.91 | 0.82–1.00* |
| Partnership injecting behaviors | ||||
| Injected with partner more than 1x/day (vs. 1x/day)† | 1.23 | 0.64–2.42 | 1.33 | 0.45–2.10 |
| Injected by partner most often† | 1.63 | 0.70–3.80 | 1.85 | 0.86–3.98 |
| Injection partner prepares drugs most often† | 0.86 | 0.36–2.06 | 0.77 | 0.35–1.65 |
| Always pooled money to pay for drugs† | 1.58 | 0.84–2.98 | 1.66 | 0.89–3.18 |
| Participant injected partner’s drug residue | 4.21 | 1.76–10.08*** | 4.20 | 1.84–9.45*** |
| Participant backloaded drugs into his/her syringeusing partner’s previously used syringe | 2.27 | 1.17–4.38** | 2.37 | 1.31–4.27** |
Note: Data from 345 HCV-negative observations representing 70 unique partnerships followed monthly for 6-months or until inactive.
†
prior 30 days.
*p≤0.10.
**p≤0.05.
***<0.001.